Biotech News
InnoCare Pharma and KeyMed Partner with Prolium Bioscience for Exclusive License Agreement
InnoCare Pharma and KeyMed Biosciences have announced an exclusive partnership with Prolium Bioscience to develop and commercialise ICP-B02 (CM355), a promising CD20xCD3 bispecific antibody. This agreement covers the non-oncology field globally and the oncology field in regions outside of Asia.
21 January 2025
Stay ahead of trends and best practices
